Nesprins are a family of multi-isomeric scaffolding proteins that were originally identified at the nuclear envelope (NE), where they bind to lamin A/C, emerin and SUN-domain containing proteins, to form the LInker of Nucleoskeleton-andCytoskeleton (LINC) complex that connects the NE to the actin cytoskeleton. However, nesprin genes also give rise to a variety of tissue specific variants of different sizes with potential roles beyond the NE. These variants are generated through alternative initiation, termination and splicing, which makes nesprin biology very complex to study due to the difficulty in generating specific antibodies and/or short interfering RNAs (siRNA) to particular isoforms. In order to distinguish genuine nesprin variants and eliminate confusion with degradation products of larger nesprin isoforms, in this chapter we discuss methods including 5' and 3' Rapid Amplification of cDNA Ends (RACE) and RT-PCR in combination with EST database searching, for identifying and validating putative nesprin isoforms. This information is essential to allow a better understanding of nesprin functions in different cell types.
Introduction
Nesprins comprise a family of multi-isomeric scaffolding proteins that were originally identified as components of the nuclear envelope (NE) [1] . There are four mammalian genes (SYNE 1-4) encoding nesprin proteins. Nesprin-1, -2 and -3 are ubiquitously expressed in human tissues, while nesprin-4 is mainly expressed in highly polarized epithelial cells [2] [3] [4] [5] . All four nesprin proteins contain a C-terminal Klarsicht/ANC-1/Syne Homology (KASH) domain, which mediates the interaction with SUN domain containing proteins (SUN1 and SUN2) at the nuclear membrane, forming the LInker of the Nucleoskeleton and the Cytoskeleton (LINC) complex [2] [3] [4] . The nesprins reside in the outer nuclear membrane (ONM) where they interact with cytoskeletal filaments. SUN 1/2 reside at the inner nuclear membrane (INM) and bind to lamin A/C directly via their nucleoplasmic domain. Therefore the LINC complex provides a physical connection between the nucleus and the cytoskeleton [5, 6] . Nesprins-1 and -2 are also able to bind to lamin A/C and emerin at the INM [1, 7] . Mutations in the genes encoding all of these proteins contribute to Emery-Dreifuss muscular dystrophy (EDMD) and dilated cardiomyopathy (DCM) [8, 9] , indicating that nuclear-cystoskeletal connection is fundamental to muscle cell function.
There are sequence diversities at the N-terminus of nesprins, allowing them to bind to different components of the cytoskeleton: actin filaments, microtubules (MT) and intermediate filaments (IF) . Nesprin-1 and nesprin-2 are defined as giant proteins due to their molecular weights of ~1 MDa and ~800 kDa respectively. Both are comprised of N-terminal paired Calponin Homology domains (CHD) that bind to F-actin, a Cterminal KASH domain, and a central Spectrin Repeat (SR)-containing rod domain, mediating protein-protein interactions [10, 11] . Nesprin-3 and nesprin-4 are characterised by a much less extended rod domain, which reflects their lower molecular weights of 110 and 42 kDa respectively [11] . Despite lacking the CHDs, they are both able to bind cytoskeleton filaments: nesprin-3 binds IFs through a plectin-binding domain, whereas nesprin-4 interacts with kinesin-1, a motor protein associated with MT networks [12, 13] .
Nesprin-1 and -2 are encoded by 146 and 115 exons respectively, which give rise to a large number of different variants [14] . Most variants have overlapping domains, indicating that the expression of nesprin variants is a highly flexible and regulated process. This flexibility is likely an adaptive response that cells require to meet the requirements of different cellular cues or stimuli. In particular in muscle tissue, nesprins not only switch isoform expression of the same gene, but also change expression between the different nesprin genes. For example, during human muscle development, expression level of nesprin-1 giant increases during early myogenesis in vitro, while nesprin-2 partially replaces nesprin-1 at the NE. Ultimately, the shorter nesprin KASH isoforms become the dominant variants during the transition from immature to mature muscle fibres in vivo [15] .
We documented that nesprin-1 and -2 give rise to a vast array of tissue specific isoforms of different sizes [14] including i) isoforms lacking the KASH domain (14 for nesprin-1 and 5 for nesprin-2); ii) isoforms lacking the CHDs (16 for nesprin-1 and 12 for nesprin-2) [16] , and iii) SR-only isoforms for nesprin-1 [17] . The isoform repertoire reflects emerging new functions of nesprins beyond the NE. The isoforms are generated by alternate promotor usage, pre-mRNA 3' end processing, and alternative splicing (including or excluding cassette exons) [14, 16, 18] . For example, nesprin-2α1 and -2α2 variants are generated via different initiation within 5' untranslated region (UTR) ( Figure 1A ) [1, 7] . Alternative splicing is another mechanism by which exons are removed from the mature nesprin mRNA. For example, nesprin-1∆KASH is generated through the removal of cassette exon 145 of nesprin-1 resulting in a stop codon at exon 146 and deletion of the KASH domain ( Figure 1B) . Similarly, nesprin-2∆KASH1 is generated through the removal of exons 111-112 ( Figure 1C ). In contrast, nesprin-2∆KASH2 is generated via different termination point through utilisation of an alternative 3'UTR juxtaposed to exon 115 via a retained intron, to produce an alternative variant ( Figure 1D ). These alternative transcript generation mechanisms have also been observed experimentally in other studies of nesprin-1 variants [19] .
All the nesprin isoforms published so far were predicted mainly using the NCBI EST (database for "Expressed Sequence Tag") [20] , but only a small subset has been verified experimentally. The variety of sizes and isoforms that can be generated make nesprin biology very complex due to the difficulty in generating (1) specific antibodies and (2) short interfering RNAs (siRNA) [21] :
(1) The use of specific antibodies is limited to a small subset of isoforms, because the antibodies available detect not only the real products of alternative splicing (of which there may be many), but often degradation products that are commonly present during the manipulation of proteins of large molecular weight [14, 15, 22] . (2) In addition, the most common event for alternate isoform formation is the use of alternative 5' and 3' UTRs, with common coding exons which complicates the exclusive knockdown of a particular isoform as it is likely to interfere with the expression of other variants. In the literature the siRNAs currently used for knocking down small isoforms also hamper the expression of the giant nesprins due to this lack of specifically targeted exon regions [14] . Moreover, the efficiency of knockdown can only be detected at the RNA level by qPCR using oligonucleotides designed specifically for each of the siRNA targeted exons, because the protein expression level is usually not verifiable due to lack of antibody specificity as described above in (1) [14] .
We have employed multiple techniques to identify and verify transcripts encoding novel nesprin variants. In some cases, these analyses have enabled us to identify variants that do have some sequence specificity at the protein level which enables the generation of more selective antibody tools. Therefore the identification and verification of novel transcripts is essential for a complete understanding of nesprin biology [1, 14, 7] . In this chapter we discuss the techniques we have used including: i) 5' and 3' Rapid Amplification of cDNA Ends (RACE) for identifying cDNA ends that represent novel 5' and/or 3' UTRs, in combination with the EST database analysis, in which there is a vast collection of partial sequences of cDNA clones available; ii) RT-PCR from multi-tissue cDNAs using alternatively combined 5' and 3' UTRs for identifying and validating putative isoforms [1, 16, 7, 23 ].
MATERIALS:
A range of gene-specific primers for amplification of the region of interest of the cDNA 
METHODS

Bioinformatics analyses
Published nesprin-1 and nesprin-2 UTRs were identified via screening the NCBI expressed sequence tag (EST) database (http://www.ncbi.nlm.nih.gov/dbEST/) [20] , which contains partial sequences of cDNA clones ranging from ~200 to ~ 700 bp. To screen for novel nesprin UTRs in the EST database:
1. Submit consecutive nesprin cDNA sequences of 1 kb with 500 bp overlapping, covering the entire gene length, to the EST database [14] . 
Rapid Amplification of cDNA Ends (RACE)
RACE is a suitable method to obtain full-length novel isoforms, and only requires knowledge of a small internal region of the cDNA sequence as well as both an adaptorspecific primer and a gene specific primer (GSP) [25] . The presence of a known specific adaptor sequence at the 5' or 3' end of the cDNA is essential for the libraries being used in RACE. Furthermore, a second PCR reaction (named nested PCR) is often required, by using the PCR product from the initial run to produce a more specific amplification product. GSP (including nested GSP) design is an important step to obtain efficient and specific PCR amplifications (see Note 2). Figure 2 and in the Marathon-ready cDNA user manual (Clontech).
Design GSP Primers for 5' or 3' RACE against the region of interest on the gene, as illustrated in
2. Perform an initial round of PCR reactions using Advantage 2 polymerase and the Marathon-Ready cDNA (Clontech) according to manufacturer's protocol, also briefly described in Table 1 , using PCR cycling parameters as follows:
94ºC for 1 min 30 cycles:
• 94ºC 30 sec (denaturation) 5. Subject each cloned fragment to sequencing. Align the obtained sequences against the appropriate NCBI species genome to identify novel cDNA ends, which will be either upstream or downstream of the cDNA region of interest.
Multi-tissue RT-PCR
To characterise the RACE PCR products and validate expression of the putative isoform at RNA level, RT-PCR is required. To amplify short transcripts, design the 5' and 3' GSPs to either existing or newly identified regions of 5' and 3' UTRs identified from the EST database analysis and/or RACE above. For larger transcripts, design a 5' GSP or 3' GSP to the newly identified regions of 5'UTR or 3'UTR, and a 3' GSP or 5'
GSP against the nearest coding exon, or primers in a range of exons (see Note 4) [14] .
1. Perform RT-PCR on a multiple tissue cDNA panel (Origene) using GC-RICH PCR system (Roche Applied Science) according to manufacturer's protocol (Table 2 and 3) , also amplifying housekeeping genes as controls. Use PCR cycling parameters as follows:
95ºC for 3 min 30-40 cycles:
• 95ºC 30 sec
• 48-55℃ 1 min (depending on the required annealing temperature for different primers)
• 68ºC 1-3 min (depending on the length of putative isoforms) 68ºC for 7 min 2. Analyse the PCR products by agarose gel electrophoresis. Excise and clone the PCR product into a pGEM-T Easy vector (Promega). Subject clones to DNA sequencing for further validation.
Alternative Splicing of Cassette Exons
Putative cassette exons of nesprins can be identified using EST databases. The resulting alternative splicing events could either occur in multiple variants or be specific for a single variant, which are also likely to be activated in a tissue specific manner [14] .
These post-transcriptional events would further increase the complexity of nesprin variants [18] . 3. Perform all PCR reactions as described in section 3.3 using GC-RICH PCR system, or as in Table 4 , using the following PCR cycling parameters: 95ºC 1 min 30 cycles:
• 95ºC 30 sec 4. For validation of 5'UTRs, the forward primer is designed within the 5'UTR and the reverse primer within the second coding exon to control for genomic contamination. For validation of 3'UTRs, the forward primer is designed within the second to last coding exon and the reverse primer within the 3'UTR to also control for genomic contamination.
5. For cassette exons (either included and excluded), forward and reverse primers should be separated by at least one exon-intron boundary to control for genomic contamination.
6. There are some examples for cassettes exons described for nesprins. When PCR amplification was carried out across nesprin-1 exon 93 (one of the cassettes detected via EST database searching), two PCR products were obtained from two different cDNA libraries. One PCR product showed the presence of the exon 93 while the other showed absence of the exon, which encodes a unique 47 amino acid peptide sequence. Nesprin-2 also showed its propensity of tissue-specific alternative splicing. For example, regarding exon 107, another cassette detected by EST, two PCR products were detected in U2OS cells, either containing or missing exon 107, which encodes a unique 23 amino acids. Only isoforms containing exon 107 were expressed in vascular smooth muscle cells [14] . 
